Przejdź do zawartości
Merck

Microbial production of phase I and phase II metabolites of midazolam.

Xenobiotica; the fate of foreign compounds in biological systems (2011-10-26)
Cyrille Marvalin, Mireille Denoux, Serge Pérard, Sébastien Roy, Robert Azerad
ABSTRAKT

Midazolam, a potent benzodiazepine derivative and a typical substrate of CYP3A4/3A5, is essentially metabolized in human into 1'-hydroxymidazolam, then eliminated as the corresponding phase II metabolite, the 1'-O-β-D-glucuronide derivative. A high yield alternative to the current multistep synthesis of 1'-hydroxymidazolam is described, using a biotransformation of midazolam by a fungal microorganism, Beauveria bassiana. The corresponding phase II metabolite, 1'-hydroxymidazolam-1'-O-β-D-glucuronide, has been then prepared by chemical synthesis (3 steps, 20% yield), or by microbial glucuronidation (one step, 20% yield) using a Streptomyces sp. strain. The use of the same Streptomyces strain allows a direct and expeditive synthesis of the same glucuronide conjugate from midazolam itself in an advantageous 17% yield.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
1′-Hydroxymidazolam
Supelco
α-Hydroxymidazolam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
α-Hydroxymidazolam solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®